Volume 29, Number 6—June 2023
CME ACTIVITY - Synopsis
Case Studies and Literature Review of Francisella tularensis–Related Prosthetic Joint Infection
Léa Ponderand, Thomas Guimard, Estibaliz Lazaro, Henry Dupuy, Olivia Peuchant, Nathalie Roch, Philippe Deroche, Tristan Ferry, Max Maurin, Aurélie Hennebique, Sandrine Boisset, Isabelle Pelloux, and Yvan Caspar
Table 3
MICs of 3 strains of Francisella tularensis subspecies holarctica obtained by broth microdilution method, France*
| Antibiotics | MICs, mg/L |
Breakpoints for susceptibility, mg/L | ||
|---|---|---|---|---|
| Case 1 | Case 2 | Case 3 | ||
| Gentamicin | 0.5 | 0.5 | 0.5 | 4† |
| Ciprofloxacin | 0.016 | 0.032 | 0.016 | 0.25† |
| Levofloxacin | 0.032 | 0.032 | 0.032 | 0.5† |
| Rifampin | 0.5 | 0.5 | 0.5 | 1‡ |
| Erythromycin | 2 | 2 | 2 | 16‡ |
| Azythromycin | 1 | 1 | 1 | 4‡ |
| Doxycycline | 0.25 | 0.25 | 0.25 | 4† |
*The assay medium was CAMHB supplemented with 2% PolyViteX (CAMHB-PVX; bioMérieux) and adjusted to pH 7.1+0.1 as recommended (17). MICs were read after 48 h of incubation and were interpreted using the Clinical and Laboratory Standards Institute susceptibility breakpoints for Francisella tularensis when available or the Haemophilus influenzae European Committee on Antimicrobial Susceptibility Testing breakpoints. †Clinical and Laboratory Standards Institute breakpoint. ‡H. influenzae European Committee on Antimicrobial Susceptibility Testing breakpoint.
Page created: March 29, 2023
Page updated: May 18, 2023
Page reviewed: May 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.